Previous news

2019

05/17/2019 87th EAS Congress (May 26-29, 2019) in Maastricht, Netherlands

EAS Congress (May 26-29, 2019) in Maastricht, Netherlands

Physiogenex will attend the 2019 EAS Congress on May 26-29, 2019 in Maastricht. Dr. François Briand, our Director of Research and Business Development, will be present at this event. He will be happy to discuss with you about your preclinical atherosclerosis projects. Please Contact us if you wish to set up an appointment. About us […]

Read more

04/08/2019 Keystone Symposia Immunometabolism, Metaflammation and Metabolic Disorders, (April 14-18, 2019) in Vancouver, British Columbia

Keystone Symposia

Physiogenex will be present at the Keystone Symposia  Immunometabolism, Metaflammation and Metabolic Disorders meeting on April 15th, 2019 during the session poster 1 (7.30 pm- 10 pm) Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our innovative NASH models: ID 1014: “GLP-1 receptor agonists reduce liver inflammation […]

Read more

04/03/2019 The International Liver Congress – Annual EASL meeting (April 10-14, 2019), in Vienna, Austria.

International Liver Congress 2019 april

Physiogenex will attend The International Liver Congress on April 12, 2019 during the Poster Session NAFLD: Experimental and pathophysiology  (9am – 5pm). Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our NASH models. Poster (#4725)  The benchmarks obeticholic acid and elafibranor show variable effects on NASH and […]

Read more

02/25/2019 Keystone Unraveling the Secrets of Kidney Disease (March 3-7, 2019), in Whistler, British Columbia, Canada.

Physiogenex will attend the Keystone Unraveling the Secrets of Kidney Disease meeting on March 4th, 2019 during the Poster Session 1 (19:30 – 22:00). Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our Diabetic Nephropathy models. Poster (#1002)  SGLT2 inhibitor dapagliflozin reduces hyperfiltration and prevents glomerular filtration […]

Read more

01/02/2019 Physiogenex to present at the NASH-TAG 2019

nash-tag

Physiogenex will present at the NASH-TAG 2019 in Park City, UT, USA, January 3rd-5th, 2019. Dr. François Briand, Director of Research and Business Development, will be presenting one poster dealing with Physiogenex NASH animal models, and a second poster dealing with the measurement of alpha-SMA protein levels in NASH/fibrosis models, using a HTRF assay kit developed […]

Read more

2018

11/29/2018 Physiogenex to present radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the WCIR 2018 in Los Angeles, CA, USA

world-congress

Physiogenex will be presenting radiotracer-based hyperinsulinemic euglycemic clamp studies and diabetic nephropathy models at the World Congress of Insulin Resistance (WCIR) 2018, in Los Angeles, CA, USA, November 29th – December 1st, 2018. The abstracts will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Thursday, November 29th, 6:30pm-7:30pm. […]

Read more

11/14/2018 Physiogenex to present the effects of green coffee and green tea in DIO mice at Obesity Week 2018 in Nashville, TN, USA

obesity-week

Physiogenex will be presenting the effects of green coffee and green tea at the Obesity Week 2018, in Nashville, TN, USA, November 11-15th, 2018. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Wednesday, November 14th, 12:00am-1:30pm, poster#3409. See the abstract If you want to set […]

Read more

11/08/2018 Physiogenex to present its 3-week ultra-fast NASH screening mouse model at the AASLD Liver Meeting 2018

AASLD

Physiogenex will be presenting its 3-week ultra-fast NASH screening mouse model mouse at the Liver Meeting 2018, in San Francisco, November 9th-13th, 2018. The effects of GLP-1 receptor agonists in this innovative NASH mouse model will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Sunday, November 11th, 12:30am-2:00pm, poster#1827. If you want […]

Read more

10/26/2018 Physiogenex and its industry partners to present at the ASN Kidney Week 2018, October the 27th, 2018, San Diego, CA, USA.

ASN Kidney Week

Physiogenex will be presenting its innovative animal models of diabetic nephropathy, namely the db/db mouse on high protein diet and the Unx/salt supplemented SDT fatty rat, at the ASN Kidney Week 2018, in San Diego, California. The studies, performed by Physiogenex and industry partners Novo Nordisk, Scohia Pharma and CLEA Japan Inc., will be presented […]

Read more

10/07/2018 Physiogenex to present at the Keystone Conference on Drivers of Type 2 Diabetes in Seoul, Korea – October 7-12th, 2018

keystone

Physiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats, a model of experimental diabetes. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session 1, on Monday October the 8th, poster #1012. If you wish to make an appointment during the […]

Read more

06/23/2018 Physiogenex to present at the American Diabetes Association Scientific Sessions in Orlando, FL, USA, June 22nd -26th 2018

ADA American diabetes Association

Physiogenex will be presenting a hyperinsulinemic euglycemic clamp study differentiating insulin analogues in STZ-rats, a model of experimental diabetes. The study will be presented by Dr. François Briand, Director of Research and Business Development, during the ADA 2018 poster session, on Monday June the 25th, from noon to 1pm, poster #1773-P. If you wish to […]

Read more

06/10/2018 Physiogenex to present at the XVIIIth International Symposium on Atherosclerosis in Toronto, Canada, June the 9th-12th, 2018

symposium

During the poster session, Physiogenex will be presenting a study dealing with the effects of evolocumab, an anti-PCSK9 antibody, in the Golden Syrian hamster model. Another study dealing with the effects of obeticholic acid on atherosclerosis and NASH in LDL-r KO mice will be presented by Dr. François Briand, Director of Research and Business Development, […]

Read more

04/26/2018 Physiogenex, Iris Pharma and CLEA Japan to present the features of diabetic retinopathy in the Uni-nephrectomized SDT fatty rat model at ARVO 2018, Honolulu, Hawaii

ARVO2018

Physiogenex, Iris Pharma and CLEA Japan will be presenting the features of diabetic retinopathy in the Uni-Nephrectomized SDT Fatty Rat, a novel Type 2 diabetic model of Diabetic Nephropathy, at the Association for Research in Vision and Ophtalmology 2018 conference (ARVO 2018) in Honolulu, Hawaii, USA. Through their partnership, Physiogenex, Iris Pharma and CLEA Japan Inc., have […]

Read more

01/05/2018 Physiogenex to present its NASH hamster model at NASH-TAG 2018

nash-tag

Physiogenex will present at the NASH-TAG 2018 in Park City, UT, USA, January 4th-6th, 2018. Dr. François Briand, Director of Research and Business Development, will be presenting a poster about the effects of obeticholic acid and elafibranor in the Diet-Induced NASH (DIN) hamster model. Looking forward to meet you there! About Physiogenex Physiogenex is a leading […]

Read more